Graphical abstract. Credit: Cell Reports (2024). DOI: 10.1016/j.celrep.2024.114967
An innovative research team has recently unveiled their findings in the article titled “Rationally designed pooled CRISPRi-seq uncovers an inhibitor of bacterial peptidyl-tRNA hydrolase” published in Cell Reports. Through the creation of a diverse collection of bacterial mutants, they have shed light on how a novel antimicrobial compound, identified using advanced artificial intelligence tools, hinders bacterial growth.
This breakthrough research has pinpointed a specific compound and its target within bacteria, presenting promising avenues for the development of a cutting-edge antibiotic treatment. The team comprises Dr. A.S.M Zisanur Rahman, Julieta Novomisky Nechcoff, and Dr. Silvia T.Cardona who are at the forefront of this exciting discovery.
The urgent global challenge posed by antibiotic resistance necessitates fresh strategies for antibiotic exploration and development to combat infectious diseases effectively.
Understanding how antibiotics function involves intricate detective work to decipher how these compounds interact with bacteria at a cellular level to halt their growth.
Drugs that target essential cellular processes within bacteria can render them hypersensitive to antibiotics, leading to their demise when exposed to these medications.
The utilization of CRISPR-interference techniques by Dr.Zisanur Rahman and his team has revolutionized the identification process of antibiotic targets without causing harm to the cells under investigation.
Stay updated with more information from phys.org.
